本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：中汇会计师事务所（特殊普通合伙）（以 下简称"中汇会计师事务所"） 证券代码： 603811 证券简称：诚意药业 公告编号：2024-036 浙江诚意药业股份有限公司 关于续聘会计师事务所的公告 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立 于杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证 券服务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 组织形式：特殊普通合伙 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 首席合伙人：余强 2、人员信息 截至 2023 年 12 月 31 日，中汇会计师事务所合伙人数量 103 人，注册会 计师人数 701 人，签署过证券服务业务审计报告的注册会计师人数 282 人。 3、业务规模 中汇会计师事务所 2023 年 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-038 浙江诚意药业股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第二次临时股东大会 召开的日期时间：2024-11-13 9 点 00 分 召开地点：浙江省温州市洞头区化工路 118 号浙江诚意药业股份有限公司洞 头制造部研发大楼 307 会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 13 日 至 2024 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股 ...

浙江诚意药业股份有限公司 第四届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：603811 证券简称：诚意药业 公告编号：2024-034 1、浙江诚意药业股份有限公司（以下简称"公司"）第四届董事会第十二次会议 于 2024 年 10 月 28 日在洞头制造部研发大楼会议室（温州市洞头区化工路 118 号）以 通讯方式召开。 2、本次会议通知和材料于 2024 年 10 月 18 日以电话及邮件等方式发送全体董事、 监事和高级管理人员。 3、本次会议应参加董事9人，实际参加董事9人。 4、本次会议由董事长颜贻意主持，公司监事、高级管理人员、证券事务代表、董 秘助理、审计部经理、投资部经理列席了本次会议。 5、本次会议召开符合《中华人民共和国公司法》和《浙江诚意药业股份有限公司 章程》等有关规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《浙江诚意药业股份有限公司 2024 年第三季度报告》 具体内容详见公司同日于指定信息披露媒体披露的《浙江诚意药业 ...

浙江诚意药业股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：603811 证券简称：诚意药业 公告编号：2024-035 具体内容详见公司同日于指定信息披露媒体披露的《浙江诚意药业股份有限 公司 2024 年第三季度报告》。 1 表决结果：3 票同意；0 票反对；0 票弃权。 1、浙江诚意药业股份有限公司（以下简称"公司"）第四届监事会第九次会 议于 2024 年 10 月 28 日在公司洞头制造部会议室（温州市洞头区化工路 118 号） 以通讯方式召开。 2、本次会议通知和材料于 2024 年 10 月 18 日以电话及邮件等方式发送全体 监事。 3、本次会议应参加监事 3 人，实际参加监事 3 人。 4、本次会议由监事会主席曾焕群主持。公司董事会秘书柯泽慧列席了本次 会议。 5、本次会议召开符合《中华人民共和国公司法》和《浙江诚意药业股份有 限公司章程》等有关规定，会议决议合法有效。 二、监事会会议审议情况 1、审议通过《浙江诚意药业股份有限公 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-031 浙江诚意药业股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●回购股份金额：本次回购资金总额不低于人民币 5,000 万元（含），不超过人民 币 10,000 万元（含），具体回购资金总额以实际使用的资金总额为准。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：本次回购股份拟用于员工持股计划或者股权激励。 ● 回购股份价格：本次回购股份价格为不超过人民币 9.66 元/股（含），该价格上 限不高于公司董事会通过本次回购股份方案决议前 30 个交易日公司股票交易均价 的 150%。 ● 回购股份方式：通过上海证券交易所交易系统以集中竞价交易方式进行。 ● 回购股份期限：本次回购用于员工持股计划或者股权激励的股份期限为自公司 董事会审议通过回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划：经问询，截至目前公司控股股东、实际控制人、 持股 5%以上的股东、董事 ...

| 回购方案首次披露日 | 2024/10/1 | | --- | --- | | 回购方案实施期限 | 2024.9.30~2025.9.29 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 240.30 | | 累计已回购股数占总股本比 | 0.73% | | 例 | | | 累计已回购金额 | 1,978.62 万元 | | 实际回购价格区间 | 8.03 元/股~8.36 元/股 | 一、 回购股份的基本情况 浙江诚意药业股份有限公司（以下简称"公司"）于 2024 年 9 月 29 日召开了 第四届董事会第十一次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司拟使用不低于人民币 5,000 万元（含），不高于人民币 10,000 万元（含）的自有资金回购公司股份，拟用于股权激励或员工持股计划，回购期限 自董事会审议通过回购股份方案之日起 12 个月内。具体情况详见公司于 2024 年 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-032 序号 股东名册 持有数量（股） 占总股本比例（%） 1 颜贻意 77,192,080 23.58 2 全国社保基金六零四组合 15,250,320 4.66 3 岑均达 8,067,360 2.46 4 柯泽慧 7,375,872 2.25 5 任秉钧 5,762,455 1.76 6 沈爱兰 5,475,006 1.67 7 庄小萍 5,416,400 1.65 8 颜茂林 5,218,649 1.59 9 中国国际金融股份有限公司 3,612,104 1.10 10 温州市洞头区诚意小额贷款股份有限 公司 3,525,900 1.08 一、公司前十大股东持股情况 注：公司前十大无限售条件股东持股情况与公司前十大股东持股情况一致。 浙江诚意药业股份有限公司 关于回购股份事项前十大股东及前十大无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 浙江诚意药业股份有限公司（以下简称"公司"）于 2024 年 9 月 29 日召开第四 ...

证券代码：603811 证券简称：诚意药业 公告编号：2024-030 浙江诚意药业股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2、回购股份所需资金未能到位，导致回购方案无法实施的风险； 重要内容提示： ● 回购股份金额：本次回购资金总额不低于人民币 5,000 万元（含），不超过人 民币 10,000 万元（含），具体回购资金总额以实际使用的资金总额为准。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：本次回购股份拟用于员工持股计划或者股权激励。 ● 回购股份价格：本次回购股份价格为不超过人民币 9.66 元/股（含），该价格 上限不高于公司董事会通过本次回购股份方案决议前 30 个交易日公司股票交易均 价的 150%。 ● 回购股份方式：拟通过上海证券交易所交易系统以集中竞价交易方式进行。 ● 回购股份期限：本次回购用于员工持股计划或者股权激励的股份期限为自公司 董事会审议通过回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划：经问询， ...

证券代码： 603811 证券简称： 诚意药业 公告编号：2024-029 浙江诚意药业股份有限公司 关于左卡尼汀注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 一、 概况 浙江诚意药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的左卡尼汀注射液《药品注册证书》，现将 具体情况公告如下： 1、药品名称： 左卡尼汀注射液 5ml：2g； 4、证书编号：2024S02090、2024S02091 12、生产企业地址：浙江省温州市洞头区化工路 118 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生 产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 1 2、剂型：注射剂 3、规格：5ml：1g； 5、药品注册标准编号：YBH19082024 6、申请事项：药品注册(境内生产) 7、注册分类：化学药品 4 类 8、药品有效期： ...

Financial Performance - The company's operating revenue for the first half of 2024 was RMB 355,789,053.38, representing a 10.89% increase compared to RMB 320,859,909.37 in the same period last year[13]. - The net profit attributable to shareholders of the listed company decreased by 15.60% to RMB 76,465,500.27 from RMB 90,599,041.78 year-on-year[13]. - The net cash flow from operating activities fell by 38.45% to RMB 66,091,401.63, down from RMB 107,386,521.93 in the previous year[13]. - The total assets of the company decreased by 5.06% to RMB 1,797,029,727.63 compared to RMB 1,892,765,912.73 at the end of the previous year[13]. - The basic earnings per share for the first half of 2024 was RMB 0.23, a decrease of 17.86% from RMB 0.28 in the same period last year[14]. - The weighted average return on net assets decreased by 1.79 percentage points to 6.27% from 8.06% year-on-year[14]. - The increase in operating revenue was primarily due to sales growth in joint and vitamin products[15]. - The decrease in net profit was mainly attributed to reduced performance from associated companies and increased losses from the subsidiary Jiangsu Chengyi[15]. - The company achieved operating revenue of 355.79 million RMB, representing a year-on-year growth of 10.89%[20]. - The net profit attributable to shareholders was 76.47 million RMB, a decrease of 15.60% compared to the same period last year[20]. Product Development and Market Position - The company’s main product, glucosamine hydrochloride capsules, has captured over 41% market share in 9 provinces and has been successfully included in centralized procurement in 22 provincial regions[19]. - The company’s product, Torasemide injection, successfully entered the national centralized procurement for the eighth batch on March 29, 2023[20]. - The company is focusing on high-end small varieties of "marine drugs" and "major disease medications" to enhance its product positioning advantage[21]. - The company plans to continue increasing product research and development as well as pursuing external acquisitions to expand its product line[21]. - The company’s glucosamine hydrochloride capsules are included in the National Medical Insurance Directory, ensuring a stable market demand[21]. - The company has developed a competitive edge by exporting raw materials and collaborating with high-end clients, achieving quality above national standards[21]. - The company has established a strong marketing network, particularly in the Shanghai Hongqiao business district, to enhance sales capabilities[24]. - The company has 14 new products in development, with key products like paracetamol injection and dobutamine hydrochloride raw materials successfully accepted for review[25]. Financial Management and Cash Flow - Sales expenses increased by 31.40% to 71.62 million yuan, primarily due to higher marketing costs in the formulation market[26]. - The operating cash flow decreased by 38.45% to 107.39 million yuan, indicating potential liquidity challenges[26]. - The net cash flow from operating activities decreased primarily due to increased payments for raw materials, employee salaries, and taxes[27]. - The net cash flow from investing activities increased due to higher prepayments for the solid preparation project in health products[27]. - The net cash flow from financing activities decreased as the new bank loan amount was reduced year-on-year[27]. - Cash and cash equivalents decreased by 39.76% to ¥177,180,581.95, mainly due to repayment of bank loans[28]. - Accounts receivable financing increased by 104.93% to ¥33,629,524.49, primarily due to an increase in customer settlements via notes[28]. - Other receivables increased by 299.23% to ¥11,467,653.05, mainly due to unreceived dividends from Kang Le Pharmaceutical[28]. - Short-term borrowings decreased by 46.43% to ¥62,849,625.56, primarily due to a reduction in bank loans[29]. - The company reported a significant increase in other non-current assets by 48.95% to ¥24,478,344.14, mainly due to prepayments for health product projects[29]. Environmental Compliance and Sustainability - The company has maintained compliance with environmental standards, with no pollution incidents reported during the first half of 2024[39]. - The company emphasizes sustainable development and aims to build a green enterprise through pollution prevention measures[39]. - The company has not faced any environmental protection administrative penalties during the reporting period[39]. - The average concentration of chemical oxygen demand (COD) emissions was 45 mg/L, with a total discharge of 0.349 tons from January to June 2024[39]. - The average concentration of ammonia nitrogen emissions was 0.994 mg/L, with a total discharge of 0.0077 tons during the same period[39]. - The company has established a focus on environmental protection and sustainable development, with no exceedances of emission standards reported[46]. - The company has implemented an emergency response plan for environmental incidents, which was approved by local environmental authorities in November 2022[54]. - The company has taken measures to reduce carbon emissions, including the installation of solar rooftop photovoltaic systems and smart energy digital management[55]. Corporate Governance and Shareholder Information - The company did not propose any profit distribution plan or capital reserve transfer to share capital during this reporting period[3]. - The company reported no non-operating fund occupation by controlling shareholders or related parties[3]. - The company has elected a new supervisor, Chen Xiaofang, to replace Su Liping, who retired due to reaching the legal retirement age[37]. - The total number of ordinary shareholders as of the end of the reporting period was 16,076[63]. - The largest shareholder, Yan Yiyi, holds 77,192,080 shares, representing 23.58% of the total shares[64]. - The second-largest shareholder, the National Social Security Fund 604 Portfolio, holds 15,250,320 shares, representing 4.66%[64]. - The company reported no significant litigation or arbitration matters during the reporting period[62]. - There were no changes in the company's share capital structure during the reporting period[63]. - The company has not disclosed any major related party transactions during the reporting period[61]. Accounting and Financial Reporting - The financial statements were approved by the board on August 19, 2024, indicating a commitment to transparency and compliance[102]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[106]. - The reporting period for the financial statements was from January 1, 2024, to June 30, 2024[107]. - The company uses RMB as its functional currency for financial reporting, with foreign subsidiaries reporting in their local currencies[109]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[112]. - The company assesses whether multiple transactions should be treated as a bundled transaction based on specific criteria[113]. - The company applies equity method accounting for joint ventures, recognizing its share of assets, liabilities, and income from joint operations[117]. - The company emphasizes the importance of accurate financial reporting and compliance with accounting standards in its financial practices[121]. Employee Compensation and Benefits - The company recognizes employee compensation liabilities, including short-term salaries, bonuses, and social insurance contributions, as liabilities during the accounting period when services are provided[177]. - The company accounts for post-employment benefits under defined contribution and defined benefit plans, with liabilities recognized based on government regulations for pension and unemployment insurance contributions[178]. - Termination benefits are recognized as liabilities when the company cannot unilaterally withdraw the plan or when costs related to restructuring are confirmed, with liabilities measured if expected to be paid beyond twelve months treated as long-term[179]. Revenue Recognition and Government Grants - The company recognizes revenue when control of the goods is transferred to the customer, which occurs upon customer acceptance and possession of the goods[186]. - Revenue is confirmed based on the completion of internal shipping procedures and receipt of customer acknowledgment, with legal ownership transferred at that point[186]. - The company recognizes government grants upon actual receipt or when there is clear evidence of eligibility for expected funds[189]. - The company adopts the total amount method for accounting government subsidies, recognizing related subsidies as deferred income and amortizing them over the useful life of the related assets[190].